Physician profile
John Ioannou
NPI 1851330328
$7,504.62
in general payments reported to CMS, 2019-2025
34 companies · $2,068 in 2025
The $2,068 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $605 · 2021: $653 · 2022: $944 · 2023: $1,071 · 2024: $1,211 · 2025: $2,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,275 · Education: $75.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,274.81 |
| Education | $75.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,103.37 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $943.95 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $893.64 | 2019-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $635.53 | 2019-2025 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $424.82 | 2020-2025 | Acthar, Terlivaz |
| Amgen INC. | $384.74 | 2019-2025 | Krystexxa, Aranesp, Tavneos |
| Horizon Therapeutics Plc | $330.75 | 2019-2023 | Krystexxa |
| Ardelyx, INC. | $282.11 | 2024-2025 | Ibsrela |
| Nxstage Medical, INC. | $265.38 | 2022-2023 | Nxstage System One |
| Novartis Pharmaceuticals Corporation | $220.52 | 2023-2025 | |
| Travere Therapeutics, INC. | $212.17 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $199.72 | 2023-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $199.06 | 2021-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $132.37 | 2022-2024 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.07 | 2024-2025 | Jardiance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $123.73 | 2024-2025 | Benlysta, Arexvy, Shingrix |
| Novo Nordisk INC | $123.29 | 2024-2025 | Ozempic, Wegovy |
| Opko Pharmaceuticals, LLC | $121.02 | 2019-2025 | Rayaldee |
| Fresenius USA Marketing, INC. | $99.62 | 2019-2025 | Velphoro, Velphoro |
| Renalytix Ai, INC. | $95.60 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Cumberland Pharmaceuticals, INC. | $92.08 | 2019-2022 | |
| Rockwell Medical, INC. | $76.04 | 2021 | |
| Mallinckrodt Enterprises LLC | $68.92 | 2019 | |
| Alexion Pharmaceuticals, INC. | $56.72 | 2022 | |
| Lilly USA, LLC | $53.21 | 2024-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $43.70 | 2020-2021 | |
| Bard Peripheral Vascular, INC. | $42.80 | 2019 | |
| Scpharmaceuticals INC. | $30.56 | 2025 | |
| Idorsia Pharmaceuticals US INC | $25.30 | 2025 | Tryvio |
| Ultragenyx Pharmaceutical INC. | $22.81 | 2022 | |
| Akebia Therapeutics INC | $19.84 | 2019 | |
| Daiichi Sankyo INC. | $19.58 | 2019 | |
| Pfizer INC. | $18.56 | 2025 | |
| Baxter Healthcare | $15.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ioannou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.